Qlaris Bio

Qlaris Bio, Inc. was founded in August 2019 and focuses on developing novel, innovative therapies with first-class mechanisms of action to address severe and debilitating ophthalmic diseases. The company’s leading platform is based on the use of ATP-sensitive potassium (KATP) channel modulators to influence the tone of blood vessels and vascular-like tissues, initially targeting ophthalmic applications.